Hussain M, et al. PROfound: Phase III study of olaparib versus enzalutamide or abiraterone for metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations. ESMO Congress 2019, abstract LBA12_PR.
Promotie: De rol van galzuren bij leverregeneratie na partiële hepatectomie
sep 2023 | Hepatologie, Maag-darm-leveroncologie